论文部分内容阅读
经过16个月,近300例的人体临床实验,由清华大学材料系崔福斋教授课题组研制成功的纳米人工骨日前获得国家食品药品监督管理局的三类植入产品试生产注册证,成为我国第一项可在市场上公开销售和应用的纳米医药产品。纳米人工骨是国家“863”、“973”支持的攻关项目,它与原有传统
After 16 months, nearly 300 cases of human clinical trials, the nano-artificial bone developed by Professor Cui Fuzhai’s research group at the Department of Materials of Tsinghua University, has recently received the Trial Product Registration Certificate from the State Food and Drug Administration, becoming China’s No. A nanopharmaceutical product that can be marketed and applied publicly in the market. Nano-artificial bone is the key project supported by the national “863” and “973”. It is in line with the original tradition.